Therapeutics Targeting Mutant KRAS
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the downstream effectors of EGFR activation, regulating cellular switches and functions and triggering intracellular signaling cascades such as the MAPK and PI3K pathways. Of the three RAS isoforms expressed in human cells, all of which were linked to tumorigenesis more than three decades ago, KRAS is the most frequently mutated. In particular, point mutations in KRAS codon 12 are present in up to 80% of KRAS-mutant malignancies. Unfortunately, there are no approved KRAS-targeted agents, despite decades of research and development. Recently, a revolutionary strategy to use covalent allosteric inhibitors that target a shallow pocket on the KRAS surface has provided new impetus for renewed drug development efforts, specifically against KRAS G12C. These inhibitors, such as AMG 510 and MRTX849, show promise in early-phase studies. Nevertheless, combination strategies that target resistance mechanisms have become vital in the war against KRAS-mutant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Research works printed but not linked: 57
- 10.1073/pnas.79.16.4848 · DOI · Paper page
- 10.1126/science.6285471 · DOI · Paper page
- 10.1038/2041104b0 · DOI · Paper page
- 10.1038/298343a0 · DOI · Paper page
- Kirsten WH, 1970, Bibl. Haematol., 1970, 246
- 10.1038/297474a0 · DOI · Paper page
- 10.1096/fasebj.3.10.2666231 · DOI · Paper page
- 10.1038/bjc.2014.215 · DOI · Paper page
- 10.1177/1947601911411084 · DOI · Paper page
- 10.1038/nrc969 · DOI · Paper page
- 10.1016/0092-8674(90)90186-I · DOI · Paper page
- 10.1016/j.cllc.2012.09.007 · DOI · Paper page
- 10.1126/science.2406906 · DOI · Paper page
- 10.1016/j.ccell.2016.02.015 · DOI
- 10.1016/j.drudis.2016.08.002 · DOI
- 10.1073/pnas.1811360116 · DOI · Paper page
- 10.1038/s41467-018-05707-2 · DOI · Paper page
- 10.1111/j.1440-1827.2010.02580.x · DOI · Paper page
- 10.1200/JCO.2009.27.4365 · DOI · Paper page
- 10.1371/journal.pone.0033003 · DOI · Paper page
- 10.1016/j.ctrv.2008.11.005 · DOI · Paper page
- 10.1007/s00384-019-03344-9 · DOI · Paper page
- 10.1038/s41388-017-0105-z · DOI · Paper page
- 10.1586/17476348.2016.1115349 · DOI · Paper page
- 10.1038/nature11252 · DOI · Paper page
- 10.1038/onc.2015.375 · DOI · Paper page
- 10.1371/journal.pone.0227366 · DOI
- 10.3389/fonc.2019.01295 · DOI
- 10.1038/s41416-019-0704-2 · DOI
- 10.1158/1078-0432.CCR-19-0197 · DOI · Paper page
- 10.2174/1389557518666180801110342 · DOI
- 10.1007/s00018-017-2564-3 · DOI
- 10.1080/10409238.2018.1431606 · DOI · Paper page
- 10.1038/nature25439 · DOI · Paper page
- 10.1016/j.bmcl.2017.06.047 · DOI
- 10.1158/1078-0432.CCR-18-3399 · DOI · Paper page
- 10.1177/1087057107307226 · DOI · Paper page
- 10.1016/j.bmc.2015.11.043 · DOI · Paper page
- 10.1021/acs.jmedchem.9b00145 · DOI · Paper page
- 10.1182/blood-2006-05-024752 · DOI · Paper page
- 10.1172/JCI65764 · DOI · Paper page
- 10.1038/nchembio.612 · DOI · Paper page
- 10.1016/j.ccr.2014.03.011 · DOI · Paper page
- 10.1016/j.advenzreg.2006.01.004 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-6656 · DOI · Paper page
- 10.1158/1541-7786.MCR-15-0506 · DOI · Paper page
- 10.1038/nm.1890 · DOI · Paper page
- 10.1111/jcmm.12618 · DOI · Paper page
- 10.1016/S0092-8674(00)80938-1 · DOI · Paper page
- 10.1038/nrc1691 · DOI · Paper page
- de Castro Carpeno J, 2013, Transl. Lung Cancer Res., 2, 142
- 10.1200/JCO.2018.36.15_suppl.9025 · DOI
- Cancer Discovery, 2019, Cancer Discov, 9, 988
- 10.1016/j.jtho.2019.08.412 · DOI
- Janne PA, 2019, A phase I clinical trial evaluating the pharmakokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors
- 10.1016/j.ctrv.2020.101974 · DOI · Paper page
- 10.1038/s12276-018-0202-2 · DOI · Paper page
Cited by
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
“In the activated state, RAS protein interacts with downstream effectors to mediate signaling pathways crucial for cellular proliferation and survival [50, 51].”
BackgroundOncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Zhang, Y., Li, C., Xia, C., Wah To, K. K., Guo, Z., Ren, C., Wen, L., Wang, F., Fu, L., & Liao, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00955-8 · Cited by 33
“MRTX849 is an orally administered and mutationselective covalent inhibitor of KRAS G12C with potent anticancer activity and it blocks KRAS signaling by irreversibly binding to the mutant KRAS G12C and locking it into an inactive GDP-bound state[18, 19].”
Background
Metadata
- Authors
- Thein, K. Z., Biter, A. B., & Hong, D. S.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2021-01-27
- Volume
- 72
- Issue
- 1
- Pages
- 349-364
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W3096441797
- Cited by
- 72
- References
- 45
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutics Targeting Mutant KRAS. https://app.cochat.ai/papers/10.1146/annurev-med-080819-033145
- The paper
- Thein, K. Z., Biter, A. B., & Hong, D. S. (2021). Therapeutics Targeting Mutant KRAS. Annual Review of Medicine. https://doi.org/10.1146/annurev-med-080819-033145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.